Mesothelioma

See our disclaimer for more information.

(c) PressZoom.com - Press Release Distribution Service - All Rights Reserved ...

Click here to find out more...

More News Click here to return to the news index » Advertising Photo Prints & Gifts Use your own photos to create fantastic personalised gifts for family, friends or yourself!

Or use the photo printing service for great value prints of your digital photos posted to you the same day » Competition Il Divo are the opera singers for the 21st century.

Fancy see...

In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single- agent and in combination chemotherapy regimens.

In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.

About CuraGen CuraGen Corporation (Nasdaq: CRGN) is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, and small molecule therapeutics, that aim to offer hope for patients with cancer, inflammatory diseases, and diabetes.

CuraGen's strategic alliances have resulted in a deep pipeline of potential therapeutics that is being developed by the Company's experienced research and development teams.

By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference in the lives of patients by bringing forward promising therapeutics that address unmet medical needs.

To further capitalize on CuraGen's extensive research and deve...